indenolol
Small moleculeexperimental
Indenolol is a beta-adrenergic blocker for the treatment of hypertension. It was investigated in the 1980s, but is not known to be marketed as of 2021. It is a derivative of a phenolic 4-indenol. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2015 (NCT03561935)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)NCC(O)COc1cccc2c1C=CC2- Mol. weight
- 247.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIndenolol ↗
- ChEMBLCHEMBL153585 ↗
Also known as
- indenolol
- indenolol
- indenolol
- indenolol
- indenolol
- indenolol
- indenolol hcl
- indenolol hydrochloride
- securpres
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03561935 | N/A | Jun 30, 2015 | Catholic University of Korea |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catholic University of Korea | Academic/Hospital | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1